Cost Reduction and Efficiency Gains from Consolidating Pharmaceutical Wholesale Sales Offices
First written in FY2022-Q1. 7 of 13 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2023: 1 of 7 companies on the "Worse" side.
6 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Accordingly, during the fiscal year, we continued to expand through M&A and grow in scale, while working to strengthen controls, including organizational restructuring, to realize the integration benefits of our past M&A activities.」
In the pharmaceutical wholesaling business, the company absorbed and merged 3 existing companies and 2 newly acquired companies into its core subsidiary, and is advancing organizational restructuring after the M&A transactions, realization of integration benefits and strengthening of sales capabilities. - 2026-04-06AdvancedEarnings
「Meanwhile, we also worked to reorganise the Group, which had expanded rapidly through M&A, and strengthen internal controls.」
The Group undertook a reorganisation, including the absorption and merger of 5 pharmaceutical wholesalers, and is strengthening internal controls across the rapidly expanded Group. - FY2026-H1AdvancedAnnual report
「Medical Ikkou Co., Ltd., a core subsidiary of the company, absorbed and merged the 3 companies it acquired during the fiscal year ended February 2025: Sato Yakuhin Hanbai Co., Ltd., Wakamatsu Yakuhin Co., Ltd. and Keiyo Sawai Yakuhin Co., Ltd. Meanwhile, in May this year, the company acquired all shares of Kochi Daiichi Yakuhin Co., Ltd., which operates a pharmaceutical wholesaling business in Kochi Prefecture, and in July of the same year acquired all shares of Saito Yakuhin Co., Ltd., which is based in Aichi Prefecture, making it a consolidated subsidiary (sub-subsidiary).」
In the pharmaceutical wholesaling business, the company completed the absorption and merger of 3 existing companies and made 2 new companies subsidiaries, advancing business integration and expansion of scale. Integration costs, however, are being incurred ahead of the benefits. - FY2025RestatedAnnual report
「To realize the benefits of the business integration between Medical Ikkou Co., Ltd. and Seibu Sawai Yakuhin Co., Ltd., carried out in September 2023, at an early stage, the company focused on reviewing its organizational structure and strengthening its sales capabilities. It also made Sato Yakuhin Hanbai Co., Ltd. and Wakamatsu Yakuhin Co., Ltd. subsidiaries in October 2024, followed by Keiyo Sawai Yakuhin Co., Ltd. in January 2025, and established a structure to offset rising costs through expansion of scale.」
The company continues to review its organizational structure and strengthen its sales capabilities following the business integration, while pursuing a policy of offsetting rising costs through expansion of scale. - FY2025-H1RestatedAnnual report
「To realize the benefits of the business integration between Medical Ikkou Co., Ltd., the company's core subsidiary, and Seibu Sawai Yakuhin Co., Ltd., carried out in September 2023, the company focused on reviewing its organizational structure and strengthening its sales capabilities.」
The company continues to review its organizational structure and strengthen its sales capabilities following the business integration with Seibu Sawai Yakuhin. In the pharmaceutical wholesaling business, revenue increased 319.2% and operating profit increased 473.4%. - FY2024-Q3RestatedAnnual report
「Against this backdrop, during the cumulative first nine months, the company consolidated the Toyohashi and Shiga sales offices into the Aichi and Mie sales offices, respectively, to strengthen and improve the efficiency of its sales activities.」
The company continues to reorganize its sales offices by consolidating the Toyohashi and Shiga sales offices into the Aichi and Mie sales offices, respectively, and to strengthen and improve the efficiency of its sales activities. - FY2024-Q1AdvancedAnnual report
「In the pharmaceutical wholesaling business, during the cumulative first quarter, the company consolidated the Toyohashi and Shiga sales offices into the Aichi and Mie sales offices, respectively, to strengthen and improve the efficiency of its sales activities.」
In the pharmaceutical wholesaling business, the company implemented specific measures to consolidate the Toyohashi and Shiga sales offices into the Aichi and Mie sales offices, respectively, strengthening and improving the efficiency of its sales activities. - FY2023-Q3RestatedAnnual report
「In the pharmaceutical wholesaling business, amid challenges in ensuring a stable supply of generic drugs, the company integrated its sub-subsidiary into a core subsidiary in March 2022 and worked to strengthen its sales structure. The earnings environment has become increasingly challenging due to the impact of drug price revisions, but the company is working to control expenses through integrated business operations.」
The company continues to strengthen its sales structure through the integration of subsidiaries and control expenses through integrated business operations. - FY2023-Q2RestatedAnnual report
「In the pharmaceutical wholesaling business, amid challenges in ensuring a stable supply of generic drugs, the company integrated 株式会社メディカル一光, the core company in the business, with its subsidiary 大豊薬品株式会社, a second-tier subsidiary of the company, in March 2022, and has worked to strengthen its sales structure. Although the earnings environment is becoming more challenging due to the impact of drug price revisions, the company is working to restrain costs through integrated business operations.」
The company continues to strengthen its sales structure through the integration of subsidiaries and control expenses through integrated business operations. - FY2023-Q1ReframedAnnual report
「Amid challenges in ensuring a stable supply of generic drugs, the company is working to improve profitability by strengthening its sales structure through integrated Group operations while restraining costs.」
The wording has shifted from the previous efficiency measures centred on consolidating sales offices to measures combining integrated Group operations through the integration of subsidiaries, a stronger sales structure and cost restraint. - FY2022-Q3RestatedAnnual report
「The company is also reducing costs and improving efficiency, and profitability is showing signs of improvement.」
The company continues its cost-reduction and efficiency-improvement initiatives and efforts to improve profitability in the pharmaceutical wholesaling business. - FY2022-Q2RestatedAnnual report
「The company is also reducing costs and improving efficiency, and profitability is showing signs of improvement.」
The company continues its cost-reduction and efficiency-improvement initiatives in the pharmaceutical wholesaling business and states that profitability is improving. - FY2022-Q1First statedAnnual report
「The company is also reducing costs and improving efficiency by consolidating its sales offices from 6 locations to 5.」
In the pharmaceutical wholesaling business, the company has explicitly described for the first time a measure to consolidate its sales offices from 6 locations to 5 and reduce costs and improve operating efficiency.